Low-dose ritonavir moderately enhances nelfinavir exposure

摘要: Background The protease inhibitor ritonavir is increasingly administered at subtherapeutic doses in highly active antiretroviral treatment, to utilize its potential for drug interactions and enhance the plasma concentrations of other concomitantly prescribed inhibitors. The addition low nelfinavirwas investigated describe extent pharmacokinetic interaction. Methods In this randomized, open-label, one-sequence crossover study, nelfinavir 1250 mg twice a day was dosed 17 days, followed by 14 days plus either 100 or 200 orally. Twenty-four healthy volunteers were evaluated pharmacokinetics nelfinavir, metabolite M8, andritonavir. Plasma measured up 12 hours after morning evening dosing, respectively, on 31. Results Ritonavir increased area under concentration-time curve(AUC) 20% (P =.024) 39% =.001) administration, respectively. AUC M8was 74% 86% dosing <.001 both). Conclusion During combination therapy clear although minor effect demonstrated but no dose shown. Clinical Pharmacology & Therapeutics (2002) 72, 123–132; doi: 10.1067/mcp.2002.126178